$5.67 Million in Sales Expected for CRISPR Therapeutics AG (NASDAQ:CRSP) This Quarter

Equities research analysts expect CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating) to post sales of $5.67 million for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for CRISPR Therapeutics’ earnings, with the lowest sales estimate coming in at $330,000.00 and the highest estimate coming in at $16.80 million. CRISPR Therapeutics posted sales of $540,000.00 during the same quarter last year, which would indicate a positive year over year growth rate of 950%. The business is scheduled to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that CRISPR Therapeutics will report full year sales of $119.24 million for the current year, with estimates ranging from $1.32 million to $727.30 million. For the next year, analysts expect that the business will post sales of $198.94 million, with estimates ranging from $2.00 million to $384.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow CRISPR Therapeutics.

CRISPR Therapeutics (NASDAQ:CRSPGet Rating) last announced its quarterly earnings results on Monday, February 14th. The company reported ($1.84) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.74) by ($0.10). The company had revenue of $12.90 million during the quarter, compared to analyst estimates of $5.39 million. CRISPR Therapeutics had a net margin of 41.28% and a return on equity of 16.21%.

A number of equities analysts have recently commented on the company. Citigroup cut their price objective on CRISPR Therapeutics from $90.00 to $64.00 and set a “neutral” rating on the stock in a report on Tuesday, March 15th. Barclays reduced their price target on shares of CRISPR Therapeutics from $148.00 to $107.00 in a research report on Wednesday, February 16th. Royal Bank of Canada dropped their price objective on shares of CRISPR Therapeutics from $117.00 to $95.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 16th. Stifel Nicolaus reduced their target price on shares of CRISPR Therapeutics to $64.00 in a report on Wednesday, February 16th. They noted that the move was a valuation call. Finally, Brookline Capital Acquisition started coverage on CRISPR Therapeutics in a research report on Monday, February 14th. They issued a “buy” rating and a $143.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $132.14.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Parametric Portfolio Associates LLC acquired a new position in CRISPR Therapeutics during the 2nd quarter worth $2,371,000. Thrivent Financial for Lutherans increased its holdings in CRISPR Therapeutics by 53.2% in the second quarter. Thrivent Financial for Lutherans now owns 3,956 shares of the company’s stock valued at $640,000 after buying an additional 1,373 shares during the last quarter. Kestra Advisory Services LLC increased its holdings in CRISPR Therapeutics by 2.2% in the third quarter. Kestra Advisory Services LLC now owns 12,472 shares of the company’s stock valued at $1,396,000 after buying an additional 272 shares during the last quarter. Avantax Advisory Services Inc. raised its stake in CRISPR Therapeutics by 15.6% during the third quarter. Avantax Advisory Services Inc. now owns 4,420 shares of the company’s stock valued at $494,000 after buying an additional 597 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its holdings in CRISPR Therapeutics by 13.4% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 50,810 shares of the company’s stock worth $5,599,000 after buying an additional 6,000 shares during the last quarter. 55.21% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics stock traded up $0.34 during midday trading on Friday, reaching $64.89. The stock had a trading volume of 26,829 shares, compared to its average volume of 1,598,174. The stock’s 50-day simple moving average is $61.76 and its 200 day simple moving average is $75.45. CRISPR Therapeutics has a twelve month low of $50.54 and a twelve month high of $169.76. The stock has a market capitalization of $4.97 billion, a PE ratio of 14.60 and a beta of 2.02.

CRISPR Therapeutics Company Profile (Get Rating)

CRISPR Therapeutics AG, a gene-editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene-editing technology that allows for precise directed changes to genomic DNA.

Recommended Stories

Get a free copy of the Zacks research report on CRISPR Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.